Payment overview · 2025
General Payments
$3,575.48
54 reported records · 14 companies
Healthcare provider profile · identity verified
Neil J Fraser, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TROY, MI · NPI 1912966649
Verified facts
What the public records show
CMS Open Payments records show Neil J Fraser, MD received $3,575.48 in general payments during 2025 across 54 reported records.
Eli Lilly and Company accounted for 78.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $2,787.15 | 78.0% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.41 | 4.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $151.08 | 4.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $124.10 | 3.5% | 2 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $100.38 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.95 | 1.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.28 | 1.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.77 | 1.2% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.51 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.48 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.02 | 0.4% | 1 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $14.06 | 0.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.37 | 0.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $12.92 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,001.15 | 28 |
| Food and Beverage | $788.33 | 24 |
| Consulting Fee | $750.00 | 1 |
| Education | $36.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $155.41 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $124.10 | 2 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $100.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.23 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.23 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.57 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $12.92 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $12.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 815 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 124 |
| Metformin Hcl | Metformin Hcl | 438 | 111 |
| Simvastatin | Simvastatin | 401 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 110 |
| Losartan Potassium | Losartan Potassium | 346 | 91 |
| Omeprazole | Omeprazole | 322 | 91 |
| Methylprednisolone | Methylprednisolone | 315 | 246 |
| Alprazolam | Alprazolam | 305 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 102 |
| Lisinopril | Lisinopril | 247 | 70 |
| Furosemide | Furosemide | 238 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 63 |
| Tramadol Hcl | Tramadol Hcl | 171 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 50 |
| Azithromycin | Azithromycin | 132 | 111 |
| Eliquis | Apixaban | 124 | 35 |
| Atenolol | Atenolol | 122 | 28 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 118 | 118 |
| Trazodone Hcl | Trazodone Hcl | 117 | 31 |
| Carvedilol | Carvedilol | 108 | 35 |
| Allopurinol | Allopurinol | 107 | 31 |
| Sertraline Hcl | Sertraline Hcl | 106 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 95 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 27 |
| Trulicity | Dulaglutide | 95 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 68 |
| Mounjaro | Tirzepatide | 92 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 34 |
| Potassium Chloride | Potassium Chloride | 80 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 30 |
| Donepezil Hcl | Donepezil Hcl | 76 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 21 |
| Ozempic | Semaglutide | 72 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 66 | 23 |
| Xarelto | Rivaroxaban | 63 | 13 |
| Meloxicam | Meloxicam | 62 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 23 |
| Synthroid | Levothyroxine Sodium | 61 | 17 |
| Lorazepam | Lorazepam | 58 | 12 |
| Montelukast Sodium | Montelukast Sodium | 58 | 19 |
| Jardiance | Empagliflozin | 57 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 15 |
| Ezetimibe | Ezetimibe | 56 | 23 |
| Memantine Hcl | Memantine Hcl | 56 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 53 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Meclizine Hcl | Meclizine Hcl | 51 | 32 |
| Bupropion Xl | Bupropion Hcl | 48 | 17 |
| Celecoxib | Celecoxib | 46 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 23 |
| Glimepiride | Glimepiride | 45 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 15 |
| Buspirone Hcl | Buspirone Hcl | 43 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Valsartan | Valsartan | 42 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Ibuprofen | Ibuprofen | 37 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Metformin Hcl Er | Metformin Hcl | 36 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 23 |
| Prednisone | Prednisone | 33 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Mupirocin | Mupirocin | 29 | 24 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 25 |
| Cefdinir | Cefdinir | 28 | 26 |
| Colchicine | Colchicine | 28 | 13 |
| Gabapentin | Gabapentin | 27 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 20 |
| Diazepam | Diazepam | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Fluconazole | Fluconazole | 23 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Mercaptopurine | Mercaptopurine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,575.48 · 54 records | Eli Lilly and Company | ABRYSVO, AIRSUPRA, ArdeoGraft, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EDARBI, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GIMOTI, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, PelloGraft, QULIPTA, REPATHA, RenoGraft, SurGraft, SurMatrix, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error